Under the S3LTEC brand, PROVIREX operates Germany’s first S3**-GMP cleanroom production facility, supporting both the advancement of its genome editing platform for HIV and the contract manufacturing of CAR-T cells. The new site at tecHHub Hamburg offers 400 m² of laboratory space, including 230 m² of cleanroom facilities spanning classes A to D, as well as dedicated quality control laboratories. Its infrastructure can accommodate up to seven automated manufacturing platforms in cleanroom class C. Preparations for GMP certification are currently in progress.
PROVIREX Genome Editing Therapies GmbH develops Advanced Therapy Medicinal Products (ATMPs) and uses its proprietary genome editing technology to precisely remove integrated viral DNA from infected cells, with the aim of curing life-threatening viral infections. The company’s primary focus is on curative HIV therapies based on a core technology utilising highly specific designer recombinases. A first-in-human clinical trial involving eight patients is planned to begin next year.
By co-locating laboratory and production activities, PROVIREX aims to improve collaboration across teams and further standardize manufacturing processes. The company has also expanded its workforce to 19 employees with specialists in manufacturing, quality control, quality assurance, cleanroom management, pharmacy, biochemistry, virology and immunology.
PROVIREX is a spin-off from the Leibniz Institute of Virology and the Dresden University of Technology. As technology transfer partner of the Leibniz Institute of Virology, Ascenion has supported the project from the beginning and holds shares in PROVIREX.
Further information: Press release of PROVIREX
